MUN:4DN

Stock Analysis Report

Executive Summary

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Denali Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

4DN

-0.01%

DE Biotechs

4.1%

DE Market


1 Year Return

-25.4%

4DN

3.1%

DE Biotechs

2.4%

DE Market


Shareholder returns

4DNIndustryMarket
7 Day0%-0.01%4.1%
30 Day0%-3.9%1.7%
90 Day0.4%-3.2%3.7%
1 Year-25.4%-25.4%3.3%3.1%5.6%2.4%
3 Yearn/a69.5%67.9%19.2%8.9%
5 Yearn/a17.3%14.7%43.2%23.7%

Price Volatility Vs. Market

How volatile is Denali Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Denali Therapeutics undervalued compared to its fair value and its price relative to the market?

3.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is Denali Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-11.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

High Growth Earnings: 4DN is forecast to remain unprofitable over the next 3 years.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Denali Therapeutics performed over the past 5 years?

-61.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets

Information is not available.


Return on Capital Employed

Information is not available.


Next Steps

Financial Health

How is Denali Therapeutics's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Information is not available.

Information is not available.


Next Steps

Dividend

What is Denali Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Information is not available.

Information is not available.

Stable Dividend: Insufficient data to determine if 4DN's dividends per share have been stable in the past.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of Denali Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Ryan Watts (42yo)

3.4yrs

Tenure

US$1,366,863

Compensation

Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. si ...


CEO Compensation Analysis

Information is not available.

Information is not available.


Management Age and Tenure

3.3yrs

Average Tenure

45yo

Average Age

Information is not available.


Board Age and Tenure

3.7yrs

Average Tenure

58yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Ownership Breakdown


Management Team

  • Marc Tessier-Lavigne (58yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$632.89k
  • Steve Krognes (49yo)

    CFO, Principal Accounting Officer & Treasurer

    • Tenure: 3.3yrs
    • Compensation: US$1.17m
  • Ryan Watts (42yo)

    Co-Founder

    • Tenure: 3.4yrs
    • Compensation: US$1.37m
  • Alex Schuth (45yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$1.08m
  • Carole Ho (45yo)

    Chief Medical Officer & Head of Development

    • Tenure: 3.6yrs
    • Compensation: US$1.37m
  • Dana Andersen

    Chief Technical and Manufacturing Officer

    • Tenure: 0.4yrs

Board Members

  • Bob Nelsen (56yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$604.24k
  • Vicki Sato (69yo)

    Chairperson

    • Tenure: 2.4yrs
    • Compensation: US$634.45k
  • Jay Flatley (65yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$633.23k
  • Marc Tessier-Lavigne (58yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: US$632.89k
  • David Schenkein (61yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$632.82k
  • Peter Klein (56yo)

    Independent Director

    • Tenure: 0.8yrs
  • Scott Biller (62yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Doug Cole (58yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$604.76k
  • Ryan Watts (42yo)

    Co-Founder

    • Tenure: 3.4yrs
    • Compensation: US$1.37m
  • Alison Goate

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Denali Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Denali Therapeutics Inc.
  • Ticker: 4DN
  • Exchange: MUN
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.795b
  • Listing Market Cap: US$1.571b
  • Shares outstanding: 94.96m
  • Website: https://www.denalitherapeutics.com

Number of Employees


Location

  • Denali Therapeutics Inc.
  • 151 Oyster Point Boulevard
  • 2nd Floor
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4DNMUN (Boerse Muenchen)YesCommon StockDEEURDec 2017
DNLINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2017

Biography

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LR ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/01/30 23:48
End of Day Share Price2018/11/02 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.